Skip to main content
. Author manuscript; available in PMC: 2017 Mar 14.
Published in final edited form as: Vaccine. 2016 Feb 10;34(12):1452–1458. doi: 10.1016/j.vaccine.2016.01.064

Table 3.

Testing of GelVac™ GI and GII.4 vaccine powders for antigen content

Vaccine Powders Expected Antigen Dose
(µg VLP/mg Powder)		 Observed Antigen Dose
(µg VLP/mg Powder)
GI VLP 15 µg/10 mg 15.46 µg/10mg
GII VLP 15 µg/10mg 16.16 µg/10mg